Lactococcus cremoris.
A probiotic strain traditionally used in cheese and buttermilk production that also supports gut health. Produces lactic acid in the gut, contributing to an acidic environment that discourages harmful bacteria. Supports microbial diversity and fermentation in the digestive tract.
Reviewed March 2026
- Category
- Probiotic
- Also filed under
- Produces nisin (natural antimicrobial peptide)Supports lactose digestionContributes to gut microbial diversity
What Lactococcus cremoris is, and what it does.
- Does it work
- Suits people building a multi-strain blend or eating cultured dairy regularly. Strain designation matters more than the species name, since the species was renamed.
- How much to take
- 1-5 billion CFU daily as part of a multi-strain probiotic. No specific standalone dosing guidelines exist because it's always used in combinations.
- Time to feel it
- Where digestive changes happen, they show up across two to four weeks of daily intake. The organism can be recovered from stool while you keep taking it.
- The first dose
- No noticeable effects on day one. Probiotic colonization takes time, and this strain doesn't produce dramatic acute effects.
- With regular use
- Weeks 3-4: possible subtle improvements in digestive regularity as gut microbial diversity increases. Don't attribute specific benefits to this single strain.
- How well tolerated
- Well tolerated. This organism has been eaten by humans since we started making cheese. GRAS status. No safety concerns whatsoever in healthy people.
- How it feels
- No distinct sensation belongs to this one organism. What shows up sits at the blend level, in day to day digestive comfort and regularity across weeks.
- The overlooked benefit
- Its cell-envelope proteinase and peptidases break casein into peptides and free amino acids. That machinery is why cultured dairy tastes nothing like the milk it started as.
1 to 10 CFU a day is where Lactococcus cremoris works.
Source: Steidler et al., 2000; Bahey-El-Din, 2012
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Supports gut microbial diversity
- Has specific probiotic health benefits
Questions people ask about Lactococcus cremoris.
- Is this the same thing as what's in my cheese?
- Exactly. Lactococcus cremoris is the primary starter culture in most cheese production. When it's in a supplement, it's the same species, just concentrated and freeze-dried.
- Why isn't this as popular as Lactobacillus probiotics?
- Lactobacillus and Bifidobacterium strains have much more clinical research as probiotics. L. cremoris is primarily a food organism. It wasn't studied as a probiotic first, it was studied as a cheese-maker.
- Can I just eat yogurt instead?
- Yogurt typically uses L. bulgaricus and S. thermophilus, not L. cremoris. For this specific organism, buttermilk and aged cheese are better sources.
- Does it survive stomach acid?
- Some strains survive better than others. L. cremoris isn't the hardiest acid survivor. Taking it with food buffers the stomach acid and improves survival rates.
- Is this the same as Lactobacillus?
- No. Lactococcus and Lactobacillus are different genera. They're related (both make lactic acid) but they're distinct organisms with different properties and different research profiles.
- Will this help with lactose intolerance?
- Possibly in a minor way. Lactic acid bacteria can produce some lactase during fermentation. But it's not a reliable treatment for lactose intolerance. Dedicated lactase supplements work better.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Lactococci and lactobacilli have been combined as mixed lactic starter cultures in dairy fermentation for well over a century. They acidify by the same lactic route while occupying slightly different growth conditions.
Lactococcus cremoris is normally delivered inside a mixed culture rather than alone, since different lactic organisms tolerate different pH and temperature ranges. Blending them raises the chance that some arrive viable.
Lactococcus cremoris ferments lactose using its own beta-galactosidase, the same enzyme activity a lactase supplement provides. The two act on the same sugar from the microbial and the supplemental side.
Colostrum carries milk oligosaccharides and lactose, the carbohydrate environment this dairy organism is adapted to. It supplies substrate rather than a second mechanism.
Charcoal binds luminal material without selecting, which includes live bacterial cells passing through. Separate the doses by several hours.
Carvacrol and thymol act on bacterial membranes broadly, including lactic acid bacteria. Taken together they reduce the viable count the product was meant to deliver.
Berberine has broad antibacterial activity in the gut lumen and reshapes community composition. Given in the same window it works against a live lactic organism.
Human enzymes cannot cleave the beta-2,1 fructose bonds in inulin, so it arrives in the colon intact and becomes fermentable substrate. Lactic acid bacteria including lactococci ferment available carbohydrate to lactate, which lowers luminal pH. Pairing a strain with a fermentable fibre is the standard synbiotic construction. The mechanism is established. Whether a given strain and fibre pair produces a measurable effect in a person is a separate question.
Short-chain fructans are among the most readily fermented prebiotic substrates for lactic acid bacteria, because the degree of polymerisation is low. Co-delivering them with a lactococcal strain gives the cells fermentable carbohydrate in the same transit window. The consequence is more lactate and a lower local pH. That is a mechanism statement, not a clinical result.
Lactococci carry beta-galactosidase activity because their ecological niche is milk, and galactooligosaccharides present the same galactosyl linkages in a non-digestible chain. That makes GOS an appropriate fermentable partner for a dairy-adapted strain. The output is organic acid production in the colon. No combination trial is being cited for this pairing.
Resistant starch escapes small-intestinal amylase and is fermented in the colon, where it favours saccharolytic populations and short-chain fatty acid production. It broadens the substrate pool available alongside an ingested strain. The confidence sits at Strong rather than Established for this specific strain pairing because the fermentation is largely carried out by resident bacteria rather than by the lactococcus itself.
Lactococci are homofermentative and produce lactate as their main end product. Butyrate producers such as Anaerostipes and Eubacterium species convert lactate and acetate into butyrate, which is the preferred fuel of colonocytes. So a lactate producer feeds into a butyrate-producing step rather than making butyrate itself. Cross-feeding is well described in culture and in fermentation models. The size of the effect in a given gut is not fixed.
Lactococci are dairy-adapted lactate producers, while bifidobacteria are colonic residents that ferment host and dietary glycans through the bifid shunt. Combining them puts organisms with different substrate preferences and different habitats into one product. Multi-strain blends are ordinary formulation practice, but a blend is not automatically additive in effect and strain-specific results do not transfer. The label stays at Promising for that reason.
Bifidobacterium lactis is among the most survivable commercial strains through gastric transit and is routinely blended with lactic acid bacteria. Pairing it with a lactococcal strain widens the range of fermentable substrates the product can act on. What is established is the practice, not a joint outcome. Any effect claim would need to name the exact strains and the study behind them.
These two turn up together in traditional dairy and vegetable ferments, where lactococci acidify quickly and plantarum tolerates the resulting low pH. That ecological pairing is why they sit together in blends. It supports compatibility rather than a health effect. Strain identity, not species, is what any effect would rest on.
Saccharomyces boulardii is a yeast, so it is unaffected by antibacterial agents that would reduce a lactococcal count, and the two occupy different niches. Blends use that difference deliberately. The compatibility argument is sound. A combined benefit is not established. Confidence is held at Promising.
Lactoferrin sequesters free iron, which restricts iron-dependent competitors, and lactic acid bacteria generally have low iron requirements compared with many Gram-negative organisms. That is the usual argument for pairing the two. It is a plausible ecological interaction drawn from established protein chemistry, not a measured synergy. Direction and size in a human gut are unquantified.
Milk proteins raise the effective pH around ingested cells and slow gastric emptying, which is why survival of lactic acid bacteria is generally higher when they are taken in a dairy matrix than in water. Lactococci are native to that matrix and carry proteolytic systems that degrade casein into peptides. The pairing is about survival and substrate, both upstream measures. It is not a clinical outcome.
Catechins including EGCG inhibit growth of many bacteria in vitro, lactic acid bacteria among them, by disrupting membranes and chelating metals. Co-formulating a large polyphenol dose in the same capsule as live cells is therefore worth checking rather than assuming. Whether the effect matters at gut concentrations after a supplement dose is not established. This is an anti-synergy flag for formulation review.
Lactococcus lactis carries the genes for de novo folate synthesis and accumulates folate during milk fermentation, which is why it is studied as a way to raise folate in fermented dairy. That is a property of the organism in a food matrix, measured as folate concentration in the ferment. It is not evidence that swallowing the strain raises a person's folate status. Confidence sits at Promising for that reason.
Partially hydrolysed guar gum is fermented in the colon without the viscosity of intact guar, which makes it easy to combine into a powder or sachet alongside a strain. It supplies fermentable substrate to the resident community. The mechanism is fibre fermentation, established for the fibre itself. The strain contribution to that fermentation is not separately quantified here.
Psyllium is only partly fermented and works largely through gel formation and water holding, so pairing it with a strain is more about transit and stool form than about feeding the organism. It is a reasonable co-ingredient in a gut formula for that reason. Calling it a prebiotic for this strain would overstate it, which is why the confidence is Promising. The mechanisms of the two ingredients are largely independent.
Talk to a doctor before taking Lactococcus cremoris if any of these apply to you: Less studied than mainstream probiotic strains, Dairy-derived (allergen concern for some). These are flags to check first, not effects Lactococcus cremoris is known to cause.
Not medical advice. Show the label to your pharmacist.What Lactococcus cremoris actually does.
This one is a homofermentative lactic acid bacterium. It ferments lactose and other sugars almost entirely into L-lactate, which acidifies its immediate surroundings and drops the local pH.
It was renamed from Lactococcus lactis subsp. cremoris to Lactococcus cremoris, so the same organism shows up under both names in papers and on labels. Matching a strain to a study means matching the strain designation, not the species name.
Lactococci run a proteolytic kit: a proteinase on the cell envelope, peptide transporters, and peptidases inside the cell. Together they chop casein into peptides and free amino acids during dairy fermentation.
The species works on branched-chain amino acids, turning leucine into 3-methylbutanal by transamination then decarboxylation. That's where the nutty note in cultured dairy comes from.
Where Lactococcus cremoris comes from.
It is grown in a milk-based broth, spun out, mixed with something that protects it during drying, and then either freeze-dried alive or deliberately heat-killed. Live and heat-killed are not interchangeable: only the live version can still ferment anything in your gut, so check which one a label means and which count it is quoting.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
Growth medium is typically milk-derived, containing lactose and casein hydrolysate, or a defined dairy-free medium where the product must avoid milk allergens. The choice affects allergen labelling more than the organism.
The strain is grown under temperature and pH control, with the pH held against its own lactate production, until biomass reaches the target density.
Cells are separated from the spent medium by centrifugation or membrane filtration and washed, which removes most residual medium components.
Biomass is blended with cryoprotectants and a carrier, then assayed by plate count for colony-forming units per gram, or by flow cytometry for total cells where the product is heat-killed.
Lyophilisation gives a live powder held at a declared count. A deliberate heat step instead gives an inactivated preparation counted as cells rather than colony-forming units.
Getting Lactococcus cremoris from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A human consumption study of the strain immobilized on oat flakes, taken daily, with blood and urine parameters as the measured endpoints. These are markers rather than clinical outcomes, and the delivery matrix is part of what was tested.Open-label trial. Bousdouni et al., 2025 (Medicina). PMID 40572644 ↗
- Genome sequencing plus preclinical laboratory characterisation of a candidate Lactococcus cremoris probiotic strain, covering the properties usually screened before human work such as genomic safety features and survival behaviour.In vitro study. Farmakioti et al., 2026 (Frontiers in Microbiology). PMID 42137817 ↗
- Administration of Lactococcus lactis subsp. cremoris changed systemic metabolite profiles in a preclinical model. These are mechanistic metabolic markers in animals and they do not carry over to people as an effect claim.Animal study. Gacasan et al., 2026 (Gut Microbes). PMID 41486553 ↗
- A genetically engineered Lactococcus lactis secreting porcine epidermal growth factor was associated with better growth performance in early-weaned piglets. The organism here is a recombinant delivery vehicle, not the food-grade strain sold as a supplement.Animal study. Wang et al., 2014 (BMC Veterinary Research). PMID 25142032 ↗
- Lactococcus cremoris produced the nutty-flavour aldehyde 3-methylbutanal in milk, and the paper traces the biosynthetic route. This is fermentation chemistry in a dairy matrix.In vitro study. Hayashizaki et al., 2026 (Journal of Dairy Research). PMID 41549732 ↗
- Characterises plasmalogen production across facultative anaerobic bacteria and in a recombinant system. Lactococci are named within the wider bacterial survey rather than being the subject.In vitro study. Irimajiri et al., 2026 (Applied and Environmental Microbiology). PMID 41427725 ↗
These are the studies our verdict leans on, chosen from the 6 we read for Lactococcus cremoris. The full linked list is below.
The studies, linked.
1 source behind our Lactococcus cremoris verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEffect of Daily Lactococcus Cremoris Spp. Consumption Immobilized in Oat Flakes on Blood and Urine Biomarkers and Human Microbiome: a Randomized Placebo-controlled Clinical TrialClinicalTrials.gov ↗54 participants, Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
